Claims for Patent: 8,715,623

Summary for Patent: 8,715,623

Title:	Pulmonary delivery of aminoglycoside
Abstract:	A dispersible powder composition comprises aminoglycoside for delivery to the lungs. The composition is effective to provide a therapeutically effective therapy via administration of less than 6 respirable unit doses by inhalation, wherein each unit dose comprises a volume of 0.30 to 0.95 mL.
Inventor(s):	Tarara; Thomas E. (Burlingame, CA), Weers; Jeffry G. (Half Moon Bay, CA), Venthoye; Geraldine (Foster City, CA)
Assignee:	Novartis AG (Basel, CH)
Application Number:	11/981,986
Patent Claims:	1. A dispersible powder composition comprising particles comprising an aminoglycoside and a phospholipid for delivery to the lungs by inhalation, wherein the particles have a geometric diameter of less than 5 microns, the composition being effective to provide a therapeutically effective therapy via administration of less than 6 respirable unit doses, and wherein each respirable unit dose comprises a volume of 0.30 to 0.95 ml. 2. A composition according to claim 1 wherein the composition comprises from about 50% to about 99% by weight aminoglycoside. 3. A composition according to claim 2 wherein the particles further comprise calcium chloride. 4. A composition according to claim 1 wherein the respirable unit dose is provided in a capsule, the capsule comprising hydroxypropylmethylcellulose. 5. A composition according to claim 1 wherein the particles have a bulk density of between 0.08 and 0.20 g/cm.sup.3. 6. A composition according to claim 1 wherein each respirable unit dose comprises a fill mass of between 25 and 50 mg, and said fill mass comprises between about 14-35 mg of aminoglycoside or salt thereof. 7. A composition according to claim 1 wherein the particles have a mass median aerodynamic diameter less than 5 microns. 8. A composition according to claim 1 having a pH of between 7 and 10. 9. A composition according to claim 1 wherein each respirable unit dose comprises a volume equivalent to a size #00 capsule or smaller capsule size. 10. A composition according to claim 1 wherein each respirable unit dose comprises a volume equivalent to a size #2 capsule or smaller capsule size. 11. A composition according to claim 1 wherein the aminoglycoside comprises tobramycin or salt thereof. 12. A composition according to claim 1 comprising calcium. 13. A composition according to claim 1 wherein the particles are spray dried particles. 14. A composition according to claim 1 wherein each respirable unit dose comprises 10-60 mg of aminoglycoside or salt thereof. 15. A composition according to claim 1 wherein the aminoglycoside comprises one or more of gentamicin, netilmicin, paramecin, tobramycin, amikacin, kanamycin, neomycin, and streptomycin. 16. A composition according to claim 1 wherein the particles have a moisture content of less than 15% by weight. 17. A composition according to claim 1 wherein the composition provides therapeutically effective therapy via administration of less than 5 respirable unit doses comprising the composition. 18. A method for administering a composition, the method comprising administering by inhalation less than 6 respirable unit doses of the composition according to claim 1 to provide at least 27.6 mg of aminoglycoside to the lungs. 19. A method for treating cystic fibrosis, the method comprising administering a pharmacologically effective amount of aminoglycoside comprising tobramycin to the lungs from a respirable unit dose according to claim 1. 20. A method for administering aminoglycoside to reduce the potential for development of bacteria in the lungs, the method comprising administering a pharmacologically effective amount of aminoglycoside to the lungs from a respirable unit dose according to claim 1. 21. A capsule comprising a composition for delivery of aminoglycoside to the lungs by inhalation, the composition including particles comprising phospholipid and aminoglycoside, the aminoglycoside comprising tobramycin, a geometric diameter less than 5 microns, a mass median aerodynamic diameter less than 5 microns, and a bulk density of greater than 0.08 g/cm.sup.3, wherein the capsule comprises a volume that is equivalent to, or less than, a capsule volume corresponding to a size #2 capsule, and wherein the capsule contains aminoglycoside or salt thereof, in an amount of 10-60 mg, whereby an effective dose of the aminoglycoside can be administered to the lungs using less than 6 capsules. 22. A pulmonary delivery method comprising administering a pharmacologically effective amount of tobramycin to the lungs by providing a composition comprising particles dispersed from less than 6 capsules by an inhalation device, the particles comprising a matrix of phospholipid and; tobramycin or a salt thereof, a bulk density of greater than 0.08 g/cm.sup.3, and having a pH of 7 or higher, wherein an effective amount of the tobramycin can be administered to the lungs in less than 6 respirable unit doses. 23. A dispersible powder composition comprising particles comprising phospholipid and tobramycin or salt thereof, the particles characterized by a geometric diameter of less than 5 microns, a mass median aerodynamic diameter of less than 5 microns, and a bulk density of between 0.08 g/cm.sup.3 and 0.20 g/cm.sup.3, wherein the amount of tobramycin or salt thereof in the particles is from about 50% to about 99%, wherein the composition is in the form of a unit dose containing the tobramycin or salt thereof in an amount of 10-60 mg, wherein a therapeutic dose of the tobramycin or salt thereof can be administered to the lungs in less than 6 respirable unit doses, each unit dose comprising a volume of 0.30 mL to 0.95 mL. 24. A respirable unit dose according to claim 23 comprising a volume equivalent to a size #0 capsule or less. 25. A composition according to claim 1 wherein the particles are hollow and porous. 26. A composition according to claim 1 wherein each respirable unit dose comprises an emitted dose greater than 70%. 27. A composition according to claim 1 wherein the particles have a bulk density of less than 0.20 g/cm.sup.3. 28. A method according to claim 22 wherein the particles comprise tobramycin or salt thereof in a potency of greater than 60%. 29. A method according to claim 22 wherein at least 27.6 mg of the tobramycin or salt thereof can be administered to the lungs in less than 6 respirable doses. 30. A composition according to claim 23 wherein the unit dose comprises a volume of less than 0.68 mL. 31. A composition according to claim 23 wherein the unit dose is contained in a size 2 capsule. 32. A composition according to claim 23 wherein the particles further comprise calcium chloride. 33. A composition according to claim 23 wherein the particles are hollow and porous.